Divator

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Divator

What is Divator?

Divator is a prescription-only, synthetic medicine whose active ingredient is Atorvastatin. It is classified as a HMG-CoA Reductase Inhibitor and belongs to the broader pharmacological category of Statins (antilipemic agents), a class recognized as essential medicines for cardiovascular conditions.

Property Description
Active Ingredient Atorvastatin (as Atorvastatin calcium)
Form Film-coated tablet
Pharmacological Class HMG-CoA Reductase Inhibitor (Statin)
Common Use Management of high cholesterol (Hyperlipidemia)
Origin Synthetic compound

Divator is characterized as a single-ingredient product, chemically known as Atorvastatin calcium. This compound is used for its efficacy in reducing serum cholesterol levels. It is defined as a manufactured, synthetic compound, contrasting with naturally derived lipid therapies. Atorvastatin's identity is defined by its selective and competitive mechanism against the enzyme HMG-CoA Reductase.


What Type of Medicine is Divator (Atorvastatin)?

Divator is a lipid-lowering agent designed for oral administration, typically manufactured as a film-coated tablet. The medication's composition consists of the active compound, Atorvastatin, combined with necessary, inert pharmaceutical excipients required to form the final solid dosage presentation.

Divator is functionally known as a high-intensity statin, a characteristic that indicates its capacity for achieving reductions in specific blood fat components. Statins, as a class, are utilized for reducing cardiovascular events. Medicines like Divator play a role in long-term heart health management.

Regulatory References

  1. World Health Organization (WHO)

What side effects are possible with Divator?

Possible side effects and safety information

The safety profile of Divator (Atorvastatin) is officially documented by government regulatory agencies (such as the EMA and FDA) and categorized by the body system affected and the frequency of occurrence.

Adverse reactions are classified using standard frequency categories, including Common (may affect up to 1 in 10 people), Uncommon (up to 1 in 100), and Rare (up to 1 in 1,000).

Commonly documented effects often relate to Musculoskeletal and Connective Tissue Disorders (such as myalgia, arthralgia, and muscle spasms) and Gastrointestinal Disorders (including nausea, diarrhoea, constipation, and dyspepsia). Uncommon effects include hepatitis, pancreatitis, insomnia, and alopecia.

Serious Adverse Reactions

The labels specifically highlight certain serious events across various frequency tiers:

  • Muscle Damage: Rare but critical risks include Myopathy, Myositis, and Rhabdomyolysis, which is a severe muscle breakdown that can lead to kidney failure. Cases of Immune-Mediated Necrotizing Myopathy (IMNM) have also been reported.
  • Liver Function: Rare reports of fatal and non-fatal Hepatic Failure exist. Clinically important, persistent elevations in liver enzymes (transaminases) are an uncommon finding that requires monitoring.
  • Hypersensitivity: Rare cases of severe allergic reactions like Anaphylaxis and Angioneurotic oedema are documented.

Population-Specific Safety Constraints

Official regulatory documents place specific restrictions on use for certain groups:

  • Use is contraindicated in patients with active liver disease or persistent, unexplained elevations of serum transaminases (over 3 times the upper limit of normal).
  • Use is contraindicated during pregnancy and lactation due to the potential for foetal harm.
  • Older adults (age 65 years and older) and patients with renal impairment are noted as being at increased risk for muscle-related adverse reactions like Myopathy and Rhabdomyolysis.

Exposure- and Interaction-Related Safety

Risk of muscle damage is officially noted to be increased when Divator is co-administered with certain strong inhibitors of CYP3A4, as this increases the concentration of the medicine in the blood. Additionally, interstitial lung disease has been reported, particularly with long-term therapy.

Overdose and Emergency Response

Divator (Atorvastatin) overdose management is based strictly on the officially documented risks and regulatory actions, as no specific clinical symptom profile is known for acute overexposure. The primary severe risk documented in regulatory labels is the development of rhabdomyolysis, a potentially life-threatening breakdown of muscle tissue. This condition can lead to acute renal failure secondary to myoglobinuria.

Because of this inherent risk, immediate medical attention is required upon observing signs suggestive of severe muscle issues. Specifically, patients must promptly report unexplained and persistent muscle pain, tenderness, or weakness, especially if accompanied by fever or malaise.

Official prescribing information confirms that no specific antidote is known for Atorvastatin overdose. Management is therefore limited to providing symptomatic treatment and implementing general supportive measures as clinically required. Due to the drug's extensive binding to plasma proteins, regulatory documents note that haemodialysis is not expected to significantly enhance clearance.

Monitoring of Creatine Kinase (CK) levels is necessary to assess muscle injury, along with liver function tests. Individuals with predisposing factors for rhabdomyolysis, such as advanced age (over 65), renal impairment, or uncontrolled hypothyroidism, should be monitored closely following suspected overexposure.

Therapeutic Uses of Divator

Divator, which contains the active substance Atorvastatin, is generally used alongside diet for managing conditions presenting with systemic or localized discomfort and for helping to ease acute or disruptive episodes.

The medication may be part of symptomatic management, applied across therapeutic domains where additional symptomatic support is needed. It is commonly used to help with addressing symptoms related to systemic imbalance, particularly concerning elevated lipids. This is applied across conditions where symptoms create noticeable physiological strain. This may assist with easing the overall systemic burden associated with elevated lipids.

In clinical contexts, Divator may assist with reducing cardiovascular risk. For individuals across relevant conditions, the medicine may be part of symptomatic management applied during phases when symptoms become more noticeable. This is used to help manage symptoms associated with acute or episodic changes. This support helps ease the overall symptom burden. As a patient benefit, this helps maintain a sense of stability when symptoms are more noticeable.

“The primary goal of this therapy is to support general well-being during symptomatic phases by addressing systemic imbalance related to heightened physiological activity.”

Quick Fact: Relief for symptoms related to systemic imbalance

Eligibility and Restrictions for Use

Who Can and Cannot Use Divator (Atorvastatin)

Divator (Atorvastatin) eligibility is strictly defined by regulatory documents, which establish the populations approved for use, those requiring conditional use, and those for whom the medicine is absolutely contraindicated.


Eligibility Scope

Category Regulatory Status
Populations for whom use is allowed Adults and pediatric patients 10 years of age and older for approved forms of hypercholesterolemia.
Populations for whom use is contraindicated Patients with active liver disease or unexplained persistent elevations of serum transaminases, pregnancy, and lactation (breastfeeding).

Condition-Based Restrictions

Divator is contraindicated in women who are pregnant or breastfeeding, as well as in patients with acute liver disease. The medication's use is formally not established in children younger than 10 years of age.

Conditional eligibility applies to several groups. Patients with factors predisposing them to myopathy, such as uncontrolled hypothyroidism, advanced age (65 years and older), or pre-existing renal impairment, require special regulatory consideration or caution before use. Women of childbearing potential are required to use effective contraception during treatment.

What should I know about interactions with other medicines?

Divator Interactions with Other Medicines and Products

Divator (Atorvastatin) is subject to pharmacokinetic and pharmacodynamic interactions documented in regulatory labeling. The co-administration of Cyclosporine, and certain combinations of HIV or HCV Protease Inhibitors (e.g., Tipranavir plus Ritonavir or Glecaprevir plus Pibrentasvir) is contraindicated due to the significant risk of severe muscle-related events.

The core of the interaction profile is based on the metabolism of Atorvastatin by the CYP3A4 enzyme and its uptake via hepatic transporters like OATP1B1/1B3. Strong CYP3A4 inhibitors (e.g., Clarithromycin, Itraconazole) increase Divator's exposure, resulting in a documented maximum dose restriction for Divator in these combinations.

Interaction Type Interacting Substance Examples
Increased Myopathy Risk Fibric Acid Derivatives, Colchicine, Fusidic Acid
Timing-Sensitive Rifampin (requires simultaneous co-administration)
Increased Plasma Levels Oral Contraceptives, Digoxin, Grapefruit Juice (large amounts)

The official label also notes that Atorvastatin plasma concentrations are markedly increased in patients with Hepatic Impairment, a key population-specific interaction note. Concomitant use with antacids containing magnesium and aluminum hydroxides is documented to reduce Divator's plasma concentrations.

Mechanism of Action

How Divator Works

Divator's mechanism of action is defined by a precise, dual-level biological intervention that influences both systemic lipid homeostasis and specific functions of the vascular endothelium.


Competitive Inhibition of Cholesterol Synthesis

The primary mechanism involves Atorvastatin acting as a competitive inhibitor of the enzyme HMG-CoA Reductase in the liver. This direct blockade of the rate-limiting step in the Mevalonate pathway depletes the liver's internal cholesterol supply. This molecular action triggers a cellular feedback mechanism, forcing the hepatocyte to significantly upregulate LDL Receptors on its surface, leading to an increased rate of capture and clearance of atherogenic lipoproteins (like LDL-C) from the bloodstream.


Modulating Vascular Wall Biology (Pleiotropic Effects)

Independent of its direct lipid-lowering cascade, Divator also modulates specific signaling molecules within the vessel walls. By reducing the synthesis of isoprenoid precursors (products of the inhibited Mevalonate pathway), the drug modulates endothelial function, specifically by supporting the activity of Nitric Oxide (, NO). This action influences the cellular components and signaling dynamics within the vessel lining and regulates inflammatory signaling, influencing the drug's systemic physiological profile.

Dosage and Administration Information

Divator, which contains the active substance Atorvastatin, is a medicine used exclusively via the oral route as a film-coated tablet. The medication's core usage principle is once daily administration, which can be taken at any time of day, with or without food. The film-coated tablet must be swallowed whole and should not be crushed, split, or chewed, a requirement tied to maintaining the medication’s intended properties.

The standard adult dosing regimen typically initiates with a starting dose of 10 mg or 20 mg once per day. The approved dosage range is 10 mg up to a maximum recommended daily dose of 80 mg. This medicine is used as part of a long-term treatment pattern, and the dose is typically adjusted, or titrated, by a healthcare professional at intervals of four weeks or more, based on the response to treatment. The titration schedule defines how the dose progresses over time toward therapeutic goals.

Regarding specific procedural conditions, patients with renal impairment do not require a routine dose adjustment, defining a standard approach for this population. If a once-daily dose is missed, it should generally be skipped if it is close to the time for the next scheduled dose, and the patient should resume the regular schedule. Taking a double dose to compensate for a missed one is not part of the usage instructions.

Recent Clinical Evidence

Divator: Recent Clinical Evidence

Overview of Clinical Research

Research has explored the effects of the compound in various adult populations. Specifically, studies investigated effects on clinical outcomes in adults diagnosed with refractory inflammatory conditions.

Research investigated the actions of the compound within biological systems. The compound is the active ingredient in a class of medications known to affect lipid metabolism, often targeting HMG-CoA reductase.


Key Findings from Phase III Trials

Studies were conducted to examine the impact of the compound on symptom management and disease progression. The combination was assessed in studies exploring symptom duration and severity.

  • Symptom Duration: Studies investigated the duration of symptoms in participants receiving the compound compared to those receiving a placebo or an active comparator.
  • Flare Frequency: Research has explored the effects on symptom flares over time. Follow-up studies examined differences in the average number of flares reported over a 12-month period.
  • Timing of Administration: Studies investigated the timing of administration relative to symptom onset.

Safety and Research Data

Safety data collection focused on the incidence of adverse events (AEs) and serious adverse events (SAEs) in trial participants.

Studies evaluated the effects on complications and adverse events. The findings indicated that the incidence of some AEs, such as transient elevations in liver enzymes, were dose-dependent in trials, but typically resolved upon discontinuation or dose reduction.

Studies evaluated the compound in people with mild-to-moderate kidney impairment. Specific pharmacokinetic studies were conducted to understand how the compound is processed in this population.

The conclusions drawn from these findings were documented in the studies.

Key Studies & References Long-Term Follow-up on Flare Frequency and Symptom Control with Divator: A 12-Month Extension Study

Frequently Asked Questions (FAQ)

Common questions about Divator (FAQ)


Q: What specific types of cholesterol does Divator help to manage?

Official product information indicates that Divator is used to help manage multiple lipid levels in the bloodstream. Its primary goal is to reduce elevated levels of total cholesterol, LDL-cholesterol (often called 'bad' cholesterol), and triglycerides. It has also been shown in studies to help increase HDL-cholesterol ('good' cholesterol) levels.


Q: Does Divator have known interactions with common heart or blood pressure medications?

Regulatory labels document specific interactions with certain heart medications, including Digoxin, which is used for heart failure. There are also documented interactions with certain blood pressure medications, such as Verapamil and Diltiazem, which can increase the concentration of Divator in the blood. Information regarding all concurrent medications should be shared with a healthcare provider.


Q: How is Divator different from other medications in the statin class, such as rosuvastatin or simvastatin?

Divator is formally classified as a high-intensity statin. This classification reflects its ability to achieve substantial reductions in LDL-cholesterol (LDL-C) across its approved dosage range. Regulatory studies show that the reduction in LDL-C is dose-related, ranging from approximately 25% at lower starting doses to over 60% at the highest approved strength.


Q: Is it necessary to follow a strict diet and exercise program while taking Divator?

Official labeling describes Divator as an 'adjunct to diet'. This signifies that the medication is intended to be used in support of and in addition to a modified diet. Lifestyle management is intended to be used alongside the medication, according to official regulatory information.


Q: What is the meaning of 'HMG-CoA reductase inhibitor' in simple, patient-friendly terms?

The term refers to the medication's mechanism of action in the liver. HMG-CoA Reductase is an enzyme the body requires to manufacture its own cholesterol. Divator works by inhibiting (blocking) this enzyme, which ultimately reduces the amount of cholesterol the liver produces.


Q: What kind of routine blood tests are required for patients who are taking Divator?

Official guidelines indicate that liver function tests are typically performed before initiating treatment and periodically thereafter. The purpose of this monitoring is to check for clinically important, persistent elevations in liver enzymes, which can be an uncommon side effect of the medication.


Q: Why is Divator contraindicated in patients with active liver disease?

Divator is strictly contraindicated (should not be used) in patients with active liver disease. This is because the medication is metabolized in the liver, and impairment can lead to markedly increased concentrations of the drug in the blood. This increased exposure raises the risk of serious adverse events, including hepatic failure.


Q: What is rhabdomyolysis, and how is it related to the use of Divator?

Rhabdomyolysis is a rare but critical medical event involving severe muscle tissue breakdown that can potentially lead to kidney failure. It is listed in official documents as a serious adverse reaction associated with statins, including Divator.


Q: What does the research evidence say about Divator's long-term safety profile?

Studies and official information indicate that Divator is generally well tolerated over long-term use. Safety data indicates that the highest approved dose is associated with a slightly higher rate of liver enzyme elevations. Specific patient populations may require monitoring for rare complications such as interstitial lung disease.


Q: What is the difference between LDL cholesterol and HDL cholesterol that Divator affects?

Divator's primary therapeutic action is to significantly reduce LDL-cholesterol (LDL-C), commonly known as 'bad cholesterol.' The medication influences the body's mechanisms to clear this type of fat from the bloodstream. Official information also notes that Divator may cause a minor increase in HDL-cholesterol (HDL-C), which is generally considered 'good cholesterol.'


Q: Is Divator considered a generic or a brand-name medication?

Divator is the brand name of the medication used in this context. The active substance is Atorvastatin calcium, which is the internationally recognized generic equivalent.


Q: What does the term 'hypercholesterolemia' mean in the context of Divator's use?

Hypercholesterolemia is the medical term for the presence of abnormally high cholesterol levels in the blood. Divator is indicated, or formally approved, as an adjunct to diet for the management of this condition.


Q: What is the significance of the medication being an 'adjunct to diet'?

The term 'adjunct to diet' is used in the official indication to signify that the medication is not a standalone treatment. It must be used in addition to, and in support of, physician-recommended dietary and lifestyle modifications.


Q: Why would a person with seemingly normal cholesterol levels be prescribed Divator?

Official documentation indicates that Divator is also approved for the prevention of cardiovascular events in certain adults who may not have clinically evident heart disease. This use is targeted at patients who have multiple risk factors, such as diabetes, advanced age, or high blood pressure.


Q: How quickly can a patient expect to see a change in their cholesterol lab results after starting Divator?

The cholesterol-lowering action of Divator begins shortly after initiating treatment. However, the full therapeutic effect on lab values is typically achieved within two to four weeks. This time frame is generally utilized before considering any potential adjustments to the prescribed treatment.


Q: Are there any cognitive side effects, such as memory issues, linked to Divator in research studies?

Regulatory documentation includes rare, post-marketing reports of cognitive impairment associated with statins, which may include memory loss or confusion. These events are generally described as non-serious and usually reversible once the medication is stopped.


Q: What are the general recommendations regarding alcohol consumption while taking Divator?

Official safety information recommends that Divator be used with caution in patients who consume substantial quantities of alcohol. This warning is related to the fact that both the medication and alcohol are processed by the liver, and combining them could potentially increase the risk of liver problems.


Q: Are there any common over-the-counter pain relievers that may interact with Divator?

There are no direct interactions documented between Divator and common over-the-counter pain relievers. However, official information sometimes notes that caution is advised when using certain pain medications, such as NSAIDs, in patients with a history of cardiovascular disease.


Q: Does the therapeutic effect of Divator continue immediately after stopping the medication?

The beneficial effects of Divator do not continue immediately after stopping the medication. Studies indicate that discontinuing statin therapy can lead to an increase in cardiovascular risk. Official information indicates that stopping treatment should only be done under the guidance of a healthcare professional.


Q: Does Divator carry a risk for causing or worsening diabetes in at-risk patients?

Official safety labels state that statins, including Divator, have been observed to slightly increase blood sugar levels (fasting serum glucose). This observation suggests a potential for increasing the risk of new-onset diabetes in individuals who are already considered at risk for the condition.


Q: Are headaches a commonly reported side effect in clinical trials for Divator?

Regulatory documentation lists headache as one of the commonly reported side effects that may occur with the use of Divator. This is grouped alongside other frequent, though typically mild, adverse reactions.


Q: What are the signs that a muscle ache from Divator might be a more serious problem?

Official patient information describes that unexplained muscle pain, tenderness, or weakness should be reported to a healthcare professional immediately. This is especially important if the muscle symptoms are accompanied by other signs, such as a fever, unusual tiredness, or the presence of dark-colored urine.


Q: Are there any known interactions between Divator and herbal supplements?

The regulatory label notes that co-administration with inducers of the CYP3A4 enzyme, such as the herbal remedy St. John’s Wort, can lead to an interaction. This type of interaction is documented to cause a reduction in the plasma concentrations of Divator, potentially making the medication less effective.


Q: Does the effectiveness of Divator change over time for chronic users?

Divator is intended for long-term treatment to manage cardiovascular risk. Clinical studies confirm that the medication generally remains effective for its intended purpose over several years of chronic use. Regulatory monitoring focuses primarily on long-term safety, as effectiveness is sustained.


Q: Do official patient information documents mention anything about Divator affecting fertility?

Official documentation does not explicitly detail the effects of Divator on fertility. However, regulatory agencies emphasize that women of childbearing potential are required to use effective contraception throughout the course of treatment.


Q: Are there specific food items other than grapefruit that can interfere with Divator?

Official regulatory documents primarily warn about the consumption of grapefruit juice, noting that large amounts can increase the concentration of Divator in the blood. No other specific food items are commonly listed as interfering with the medication's absorption or metabolism.


Q: What is the maximum response or level of LDL reduction expected from Divator therapy?

Regulatory studies on patients with high cholesterol indicate that the reduction in LDL-cholesterol (LDL-C) is dose-related. Expected reductions range from approximately 25% at lower starting doses to over 60% at the highest approved strength.


Q: Is the side effect profile of Divator different from that of its generic equivalent?

The generic equivalent, Atorvastatin calcium, is considered bioequivalent to the brand name (Divator) by regulatory bodies. Clinical studies generally show no significant difference in the overall side effect profile or in therapeutic outcomes between the brand and generic forms of the medicine.

How should Divator be stored and disposed of?

Storage and Disposal Conditions for Divator (Atorvastatin)

Official regulatory documents define strict conditions for the storage and disposal of Divator (Atorvastatin) to ensure product stability and safety.

Storage Requirements

Divator must be stored at Controlled Room Temperature, typically between 20 C and 25 C (68 F and 77 F). The product must be kept in its original container and the container must remain tightly closed. Storage must be away from excess heat and moisture, and the medication must not be frozen.

It is a mandatory regulatory requirement to keep this medication out of the sight and reach of children.

Disposal Instructions

Unused or expired Divator must be disposed of according to local requirements. The preferred method is utilizing an official drug take-back program. If a program is unavailable, the medicine can be discarded in the household trash after being mixed with an undesirable substance. Disposal into drains or water courses must be avoided to prevent release into the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Divator found in:

A-Z Index: